Literature DB >> 33625503

Tumor metabolism and neurocognition in CNS lymphoma.

Huimin Geng1,2, Mazie Tsang3, Lakshmipriya Subbaraj4, Joseph Cleveland4, Lingjing Chen4, Ming Lu3,4, Jigyasa Sharma5, Daniel B Vigneron5, John Kurhanewicz5, Marisa LaFontaine5, Tracy Luks5, Bruce A Barshop6, Jon Gangoiti6, Javier E Villanueva-Meyer2,5, James L Rubenstein2,3.   

Abstract

BACKGROUND: The mechanistic basis for neurocognitive deficits in central nervous system (CNS) lymphoma and other brain tumors is incompletely understood. We tested the hypothesis that tumor metabolism impairs neurotransmitter pathways and neurocognitive function.
METHODS: We performed serial cerebrospinal fluid (CSF) metabolomic analyses using liquid chromatography-electrospray tandem mass spectrometry to evaluate changes in the tumor microenvironment in 14 patients with recurrent CNS lymphoma, focusing on 18 metabolites involved in neurotransmission and bioenergetics. These were paired with serial mini-mental state examination (MMSE) and MRI studies for tumor volumetric analyses. Patients were analyzed in the setting of the phase I trial of lenalidomide/rituximab. Associations were assessed by Pearson and Spearman correlation coefficient. Generalized estimating equation (GEE) models were also established, adjusting for within-subject repeated measures.
RESULTS: Of 18 metabolites, elevated CSF lactate correlated most strongly with lower MMSE score (P < 8E-8, ρ = -0.67). High lactate was associated with lower gamma-aminobutyric acid (GABA), higher glutamate/GABA ratio, and dopamine. Conversely, high succinate correlated with higher MMSE scores. Serial analysis demonstrated a reproducible, time-dependent, reciprocal correlation between changes in lactate and GABA concentrations. While high lactate and low GABA correlated with tumor contrast-enhancing volume, they correlated more significantly with lower MMSE scores than tumor volumes.
CONCLUSIONS: We provide evidence that lactate production and Warburg metabolism may impact neurotransmitter dysregulation and neurocognition in CNS lymphomas. We identify novel metabolomic biomarkers that may be applied in future studies of neurocognition in CNS lymphomas. Elucidation of mechanistic interactions between lymphoma metabolism, neurotransmitter imbalance, and neurocognition may promote interventions that preserve cognitive function.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  lymphoma metabolism; neurocognition; neurotransmitter pathways

Mesh:

Substances:

Year:  2021        PMID: 33625503      PMCID: PMC8485453          DOI: 10.1093/neuonc/noab045

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  48 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans.

Authors:  J I Brown; A J Baker; S J Konasiewicz; R J Moulton
Journal:  J Neurotrauma       Date:  1998-04       Impact factor: 5.269

3.  In the aging housefly aconitase is the only citric acid cycle enzyme to decline significantly.

Authors:  Connie S Yarian; Rajindar S Sohal
Journal:  J Bioenerg Biomembr       Date:  2005-04       Impact factor: 2.945

4.  Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects.

Authors:  Emil F Coccaro; Royce Lee; Paul Vezina
Journal:  J Psychiatr Res       Date:  2013-06-18       Impact factor: 4.791

5.  Validation of a dual LC-HRMS platform for clinical metabolic diagnosis in serum, bridging quantitative analysis and untargeted metabolomics.

Authors:  Ilya Gertsman; Jon A Gangoiti; Bruce A Barshop
Journal:  Metabolomics       Date:  2014-04-04       Impact factor: 4.290

6.  Increased transmitter amino acid concentration in human ventricular CSF after brain trauma.

Authors:  A M Palmer; D W Marion; M L Botscheller; D M Bowen; S T DeKosky
Journal:  Neuroreport       Date:  1994-12-30       Impact factor: 1.837

7.  Cerebrospinal fluid choline in extrapyramidal disorders.

Authors:  S M Aquilonius; B Nyström; J Schuberth; A Sundwall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-10       Impact factor: 10.154

8.  Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

Authors:  Tracy Batchelor; Kathryn Carson; Alison O'Neill; Stuart A Grossman; Jane Alavi; Pamela New; Fred Hochberg; Regina Priet
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

9.  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

Authors:  Andrés J M Ferreri; Jean-Yves Blay; Michele Reni; Felice Pasini; Michele Spina; Achille Ambrosetti; Antonello Calderoni; Andrea Rossi; Vittorio Vavassori; Annarita Conconi; Liliana Devizzi; Françoise Berger; Maurilio Ponzoni; Bettina Borisch; Marianne Tinguely; Michele Cerati; Mario Milani; Enrico Orvieto; Juvenal Sanchez; Christine Chevreau; Stefania Dell'Oro; Emanuele Zucca; Franco Cavalli
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

10.  Increased glutamate/GABA+ ratio in a shared autistic and schizotypal trait phenotype termed Social Disorganisation.

Authors:  Talitha C Ford; Richard Nibbs; David P Crewther
Journal:  Neuroimage Clin       Date:  2017-07-24       Impact factor: 4.881

View more
  3 in total

Review 1.  Improving Technology to Diagnose Tuberculous Meningitis: Are We There Yet?

Authors:  Kenneth Ssebambulidde; Jane Gakuru; Jayne Ellis; Fiona V Cresswell; Nathan C Bahr
Journal:  Front Neurol       Date:  2022-05-30       Impact factor: 4.086

2.  Tracking the neurobiology of cognitive dysfunction in primary CNS lymphoma?

Authors:  Milena Pertz; Uwe Schlegel
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

Review 3.  Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.

Authors:  Yujia Zhai; Xiangxiang Zhou; Xin Wang
Journal:  Ther Adv Med Oncol       Date:  2022-05-04       Impact factor: 5.485

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.